Effects of different peritoneal dialysis fluids on the Th1/Th2 balance

European Cytokine Network

Volumn 22, Issue 1, 2011, Pages 24-31

  Libetta, Carmelo ^a   Esposito, Pasquale ^a   Sepe, Vincenzo ^a   Guastoni, Carlo ^b   Zucchi, Manuela ^c   Meloni, Federica ^a   dal Canton, Antonio ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Hospital of Legnano   (Italy)

^c Dialysis Unit Voghera Hospital   (Italy)

Author keywords

Biocompatibility; Icodextrin; Peritoneal dialysis; Peritoneal fluids; Th1 Th2 imbalance

Indexed keywords

BICARBONATE; C REACTIVE PROTEIN; DIANEAL; EXTRANEAL; GAMMA INTERFERON; GLUCOSE; ICODEXTRIN; INTERLEUKIN 4; LACTIC ACID; PERITONEAL DIALYSIS FLUID; PHYSIONEAL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; MONOCYTE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PERITONITIS; TH1 CELL; TH2 CELL;

AGED; DIALYSIS SOLUTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONEUM; TH1 CELLS; TH2 CELLS;

EID: 79958030687     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2011.0280     Document Type: Article

References (46)

1. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007; 20: 440.
2. Lim WH, Kireta S, Leedham E, Russ GR, Coates PT. Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients. Kidney Int 2007; 72: 1138.
3. Nitta K, Nitta K, Akiba T, et al. Characterization of TH1/TH2 profile in uremic patients. Nephron 2002; 91: 492.
4. Street NE, Mosmann TR. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J 1999; 5: 171.
5. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133.
6. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28: 454.
7. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057.
8. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345.
9. Cabrera R, Tu Z, Xu Y, et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004; 40: 1062.
10. Velthuis JH, Mol WM, Weimar W, et al. CD4+CD25bright+ regulatory T cells can mediate donor nonreactivity in long-term immunosuppressed kidney allograft patients. Am J Transplant 2006; 6: 2955.
11. Libetta C, Rampino T, Dal Canton A. Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients. Am J Kidney Dis 2001; 38: 286.
12. Zamauskaite A, Perez-Cruz I, Yaqoob MM, Madrigal JA, Cohen SB. Effect of renal dialysis therapy modality on T cell cytokine production. Nephrol Dial Transplant 1999; 14: 49.
13. Libetta C, De Nicola L, Rampino T, De Simone W, Memoli B. Inflammatory effects of peritoneal dialysis: evidence of systemic monocyte activation. Kidney Int 1996; 49: 506.
14. Chiesa S, Vigo G, Cappa F, et al. Peritoneal T cell responses can be polarized toward Th1 or Th2 in children on chronic peritoneal dialysis. Artif Organs 2004; 28: 750.
15. Dasgupta MK, Larabie M, Halloran PF. Interferon-gamma levels in peritoneal dialysis effluents: relation to peritonitis. Kidney Int 1994; 46:475.
16. ter Wee PM, Beelen RH, van den Born J. The application of animal models to study the biocompatibility of bicarbonate-buffered peritoneal dialysis solutions. Kidney Int 2003; 88: S75.
17. Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. Kidney Int 2004; 66: 1257.
18. Williams JD, Topley N, Craig KJ, et al. Euro Balance Trial Group. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408.
19. Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008; 73: 200.
20. Li FK, Chan LY, Woo JC, et al. A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD. Am J Kidney Dis 2003; 42: 173.
21. Zhe XW, Tian XK, Cheng L, Wang T. Effects of peritoneal resting on peritoneal fluid transport kinetics. Perit Dial Int 2007; 27: 575.
22. Libetta C, Sepe V, Zucchi M, Portalupi V, Meloni F, Dal Canton A. The effect of sirolimus- or cyclosporine-based immunosuppression effects on T-cell subsets in vivo. Kidney Int 2007; 72: 114.
23. Wang HH, Lin CY. Interleukin-12 and -18 levels in peritoneal dialysate effluent correlate with the outcome of peritonitis in patients undergoing peritoneal dialysis: implications for the Type I/Type II T-cell immune response. Am J Kidney Dis 2005; 46: 328.
24. Memoli B, Libetta C, Rampino T, Dal Canton A, Conte G, Andreucci VE. Hemodialysis related induction of interleukin-6 production by blood mononuclear cells. Kidney Int 1992; 42: 320.
25. Williams JD, Craig KJ, Topley N, et al. Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470.
26. Mortier S, Lameire NH, De Vriese AS. The effects of peritoneal dialysis solutions on peritoneal host defense. Perit Dial Int 2004; 24: 123.
27. Bos HJ, Struijk DG, Tuk CW, et al. Peritoneal dialysis induces a local sterile inflammatory state and the mesothelial cells in the effluent are related to the bacterial peritonitis incidence. Nephron 1991; 59: 508.
28. Tauer A, Zhang X, Schaub TP, et al. Formation of advanced glycation end products during CAPD. Am J Kidney Dis 2003; 41(Suppl. 1): S5.
29. Kim YL. Update on mechanisms of ultrafiltration failure. Perit Dial Int 2009; 29: S123.
30. Hoff CM. In vitro biocompatibility performance of Physioneal. Kidney Int 2003; (Suppl.): S57.
31. Park MS, Kim JK, Holmes C, Weiss MF. Effects of bicarbonate/ lactate solution on peritoneal advanced glycosylation end-product accumulation. Perit Dial Int 2000; 20: S33.
32. Park SH, Lindholm B. Definition of metabolic syndrome in peritoneal dialysis. Perit Dial Int 2009; 29 (Suppl. 2): S137.
33. Frampton JE, Plosker GL. Icodextrin: a reviewof its use in peritoneal dialysis. Drugs 2003; 63: 2079.
34. Wu HY, Hung KY, Hu FC, et al. Risk factors for high dialysate glucose use in PD patients -A retrospective 5-year cohort study. Perit Dial Int 2010; 30: 448.
35. Mistry CD, Gokal R, Peers E. Arandomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 1994; 46: 496.
36. Davies SJ, Woodrow G, Donovan K, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338.
37. Lin A, Qian J, Li X, et al. Icodextrin National Multi-center Cooperation Group. Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid. Clin J Am Soc Nephrol 2009; 4: 179.
38. Davies SJ, Brown EA, Frandsen NE, et al. EAPOS Group. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005; 67: 1609.
39. Ha H, Cha MK, Choi HN, Lee HB. Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int 2002; 22: 171.
40. Posthuma N, ter Wee PM, Niessen H, Donker AJ, Verbrugh HA, Schalkwijk CG. Amadori albumin and advanced glycation endproduct formation in peritoneal dialysis using icodextrin. Perit Dial Int 2001; 21: 43.
41. Plum J, Lordnejad MR, Grabensee B. Effect of alternative peritoneal dialysis solutions on cell viability, apoptosis/necrosis and cytokine expression in human monocytes. Kidney Int 1998; 54: 224.
42. Moriishi M, Kawanishi H. Icodextrin and intraperitoneal inflammation. Perit Dial Int 2008; 28: S96.
43. Martikainen TA, Teppo AM, Grönhagen-Riska C, Ekstrand AV. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane?. Perit Dial Int 2005; 25: 453.
44. Bacharaki D, Thodis E, Passadakis P, Kantartzi K, Kriki P, Vargemezis V. Comparative in vitro study of different peritoneal dialysis solutions on cytokine production by peripheral blood mononuclear cells. Nephron Clin Pract 2009;113: c321.
45. Mortier S, De Vriese AS, McLoughlin RM, et al. Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. J Am Soc Nephrol 2003; 14: 1296.
46. Davenport A. Peritonitis remains the major clinical complication of peritoneal dialysis: the London, UK, peritonitis audit 2002-2003. Perit Dial Int 2009; 29: 297.